This research purports to check the safety, tolerance of non-biological DMARDs and to adjust the amount used observing local, general side effects can occur after injecting CreaVax-RA, is auto-derived dendritic cel, to patient is taking non-biological DMARDs for rheumatoid arthritis and to obtain data as to the effectiveness of the medicine observing specific antigen immunologic inhibition act on rheumatoid arthritis of the adjusted amount used.

Treatment

Investigational Product: CreaVax-RA
- Dosage: First test dosage (A) 5 x 10^6 cells/injection 
          Next level dosage (B) 1.5 x 10^7 cells/injection 
- Freqeuncy: 3 injections every two weeks, after four weeks 2 injections every two weeks(W0, W2, W4, W8, W10)

Arm Label

Target Number of Participant

Arm Type

Arm Description

Active rheumatoid arthritis patients modulated with usual DMARDs

Gender

Age

Description

1. Patient diagnosed that he/she is with rheumatoid arthritis according to ACR rheumatoid arthritis classification standard reformed in 1987.
2. Patient is over 19 and under 71 years old.
3. Patient of who rheumatoid arthritis functional status is classified as Class I, II. III according to ACR classification standard. 
4. Patient is with benign Anti CCP found by screening.
5. Patient of who ESR (Erythrocyte Sedimentation Rate) ≥ 28 mm/hour or CRP (C-reactive Protein) ≥ 1.0 mg/dL found by screening
6.Patient taking non-biological DMARDs such as MTX with the same quantity before screening for more than 8 weeks and this treatment can be applied for the time being. 
7. Patient taking oral corticosteroid (prednisone of which amount used is 10mg/day or less) and NSAIDs before screening for more than 4 weeks.
8. Patient agreed to contracept until 6months after the clinical trial.
9. Patient participates in the clinical trial voluntarily signing up.

1. Patient had major surgery such as joint surgery within 8 weeks before screening 
2. Patient is currently with rheumatoid arthritis or rheumatoid autoimmune disease 
3. Patient is with serious rheumatoid arthritis complication.
4. Patient is with rheumatoid arthritis Class IV according to ACR classification 
5. Patient is currently with or had inflammatory joint disease other than arthritis.
6. Child patient is with rheumatoid arthritis. 
7. Patient is in wash out period after taking the medicine before screening.
8. Patient took immunosuppressant within 3 months registration.
9. Patient took such treatments as V-globulin IV, Plasmapheresis and Prosorba within 24 weeks 
10. Patient took other clinical trial medicines within 12 weeks 
11. Patient is with serious cardiovascular system, nervous system, respiratory system, endocrine 
    system and gastrointestinal system related disease cannot be controlled.
12. Patient is with serious high blood pressure.
13. Patient could be with renal, liver and biliary tract function disorder. 
14. Patient with serious asthma, psoriasis, Inflammatory bowel disease cannot be controlled.
15. Patient is currently with gastric ulcer, ulcerative stomatitis, ulcerative colitis 
16. Patient is currently with Bacterial, viral, fungal, mycobacterial other infectious diseases 17. Patient is reluctant to have treatment of latent tuberculosis found by screening 
18. Patient needs to be hospitalized due to infection diseases, had antibiotics administration in 
    the vein 4 weeks before screening or oral administration 2 weeks before screening.
19. Patient is currently with or had primary and secondary immunodeficiency syndrome.
20. Patient was prescribed as malignant tumor within a decade.
21. Pregnant woman, nursing woman or woman is going to be pregnant within 6 months. 
22. Patient is judged by the P.I as the patient is not suitable for the research.
23. Serum creatinine > ULN/ 24. ALT or AST > 1.5 times of ULN.

adverse event & clinical test results

treatment period

Tolerated Dose

4 weeks later after the last injection

Induction of antigen specific immune suppression for rheumatoid arthritis

Before the first injection(W0), W8, W14

ACR20/50/70 Response Rate

treatment period